Scanfil (SCANFL) Q1 2025 earnings summary

Executive summary

• Q1 2025 was a transition quarter with stable operational performance, significant project ramp-ups, and new product introductions, supporting a positive outlook for the year.

• Regional segment reporting and EBITDA/EBITA as new key indicators were introduced for greater transparency.

• Strong financial position enables both organic and inorganic growth, with investments and integration activities, especially in Malaysia, supporting future expansion.

• Americas and APAC segments delivered strong growth, while Central and Northern Europe saw declines due to project-based demand and industrial customer softness.

• No order cancellations due to trade war; local-for-local manufacturing strategy is driving resilience.

Financial highlights

• Revenue/turnover for Q1 was EUR 192.6 million, a 3.2% decline year-over-year; Americas +35.8%, APAC +30.2%, Central Europe -17.8%, Northern Europe -12.3%.

• Comparable EBITDA/EBITA reached EUR 12.6 million (6.5% margin), nearly flat compared to last year.

• EBIT was EUR 11.9 million (6.2% margin), slightly down from 6.4% last year.

• Net profit was EUR 8.3 million, down from EUR 9.8 million; EPS EUR 0.13 (0.15 last year); return on equity at 11.2%.

• Cash flow from operations was EUR 11 million, up from EUR 9.7 million; free cash flow EUR 9.3 million.

Outlook and guidance

• Revenue/turnover guidance for 2025 reiterated at EUR 780–920 million; comparable EBITDA/EBITA guidance at EUR 55–68 million.

• Q2 expected to see less impact from ramp-up projects, with positive trends in revenue and profitability continuing.

• Strong pipeline in Energy & Cleantech and Medtech & Life Science segments supports confidence in outlook.

• Guidance metric changed from adjusted operating profit to comparable EBITA.

• Continued emphasis on cost and inventory management, and active M&A pipeline.